Monopar Therapeutics (MNPR) Income towards Parent Company (2017 - 2019)
Historic Income towards Parent Company for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' Income towards Parent Company fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Sep 2020 it was -$1.2 million, marking a year-over-year increase of 6956.95%. This contributed to the annual value of -$4.3 million for FY2019, which is 3104.1% down from last year.
- According to the latest figures from Q4 2019, Monopar Therapeutics' Income towards Parent Company is -$1.2 million, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
- Over the past 5 years, Monopar Therapeutics' Income towards Parent Company peaked at -$373839.0 during Q1 2017, and registered a low of -$14.9 million during Q3 2017.
- In the last 3 years, Monopar Therapeutics' Income towards Parent Company had a median value of -$828354.0 in 2018 and averaged -$2.0 million.
- Examining YoY changes over the last 5 years, Monopar Therapeutics' Income towards Parent Company showed a top increase of 9551.92% in 2018 and a maximum decrease of 14001.24% in 2018.
- Over the past 3 years, Monopar Therapeutics' Income towards Parent Company (Quarter) stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
- Its Income towards Parent Company was -$1.2 million in Q4 2019, compared to -$759448.0 in Q3 2019 and -$932109.0 in Q2 2019.